• Curaleaf Holdings (TSX:CURA) expanded its supply agreement with Cannara Biotech to a potential C$34 million over two years.

• The enlarged deal grants Cannara broader access to Curaleaf's international distribution network for medical cannabis products.

• Management framed the move as part of Curaleaf's push to build business beyond North America and into overseas medical markets.

• The expanded Cannara supply agreement is only one part of the Curaleaf story that investors should weigh. Take a look at 3 warning signs (1 major) we have identified for Curaleaf Holdings.

Consider widening your watchlist to other cannabis related stocks that also sit alongside higher yielding names in 2 dividend fortresses .

Curaleaf Holdings operates a retail and wholesale cannabis platform in the United States and abroad, so wider access to its network can matter for partners that rely on established medical channels. With a market value of about CA$3.8b, the group already carries meaningful scale within the pharmaceuticals-focused cannabis segment.

4 things going right for Curaleaf Holdings that this headline doesn't cover.

Curaleaf's Cannara deal leans into the international expansion catalyst, but keeps execution risk in focus

For Curaleaf Holdings, this enlarged Cannara supply pact directly feeds the international expansion catalyst in its Narrative. The arrangement leans on Curaleaf's overseas medical infrastructure and supports the push to diversify revenue streams beyond the more crowded U.S. market. At the same time, it brushes up against a key risk already flagged for the group, the pressure from costly international build outs and the possibility that newer medical markets scale more slowly than hoped. Investors are effectively being asked to weigh the value of extra volume flowing through Curaleaf's network against that ongoing execution and regulatory burden in markets that are still developing.

See how these catalysts shape Curaleaf Holdings' path to a CA$18.54 fair value .

The clearest test of this read sits in how much product Cannara actually ships into Curaleaf's network over the next two years and how that shows up in segment disclosures for international medical operations once both groups start reporting against the higher C$34 million ceiling.

The Curaleaf Holdings question most headlines skip

For a business this large, investors often pay close attention to who is calling the shots and how those leaders are rewarded for their decisions. See who is actually steering Curaleaf Holdings, and how they are paid .